Research confirms benefits of side-actuated nasal spray

Published: 8-Feb-2010
Ingredients Drug Delivery Research & Development Pharmaceutical

Valois Pharma's side-actuated nasal spray has excellent ergonomics, is comfortable to handle and easy to actuate, research by the French pharmaceutical company reveals.

Valois Pharma's side-actuated nasal spray has excellent ergonomics, is comfortable to handle and easy to actuate, research by the French pharmaceutical company reveals.

The side-actuated nasal spray consists of a standard actuator coupled with a customisable shell and cap.

The research, carried out in the UK last November involving 10 regular nasal spray users, as well as six doctors (GPs and ENT specialists), showed that the side-actuated delivery device has the three advantages mentioned above.

Patients also thought a slightly longer nozzle would improve the placement of the device in the nostril when the device is actuated, and Valois will further investigate this.

The company says new user research will be carried out in the US in the coming months to confirm the results of the current study.




See more

You may also like

Research & Development

Vanda Pharmaceuticals secures FDA approval for motion sickness treatment NEREUS

Read more
The US FDA has approved Vanda Pharmaceuticals’ NEREUS (tradipitant) for the prevention of vomiting induced by motion, marking a historic regulatory milestone and introducing the first novel pharmacological option for motion sickness in more than four decades

Trending Articles

  1. When science meets security: the future of small molecule outsourcing Looking across 2025 and into 2026, chemical and pharmaceutical manufacturing is navigating a period of rapid transition, with trends emerging that will influence competitiveness for years to come
  2. CHITOSE and FUJIFILM Biosciences form strategic alliance to drive global innovation and biopharmaceutical manufacturing Collaboration formed to accelerate biopharmaceutical manufacturing, combining high-performing CHO-MK cells and GMP-manufactured culture media
  3. Zephyrus Innovations receives 510(k) clearance from FDA for VaporShield CSTD With CSTDs now required in the US under USP<800> legislation, VaporShield is the first direct injection CSTD for subcutaneous and intramuscular administration
  4. New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research Osaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
  5. Med Uni Graz researchers present a new approach to targeted therapy for leukaemia Acute myeloid leukaemia (AML) is a cancer of the haematopoietic cells that causes the uncontrolled proliferation of certain immature blood cells

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Research & Development

Vanda Pharmaceuticals secures FDA approval for motion sickness treatment NEREUS

The US FDA has approved Vanda Pharmaceuticals’ NEREUS (tradipitant) for the prevention of vomiting induced by motion, marking a historic regulatory milestone and introducing the first novel pharmacological option for motion sickness in more than four decades
Research & Development

A new era in diabetes: five biotech companies moving past daily insulin injections

From cell-encapsulation platforms and islet transplantation breakthroughs to next-generation GLP-1 combinations and connected insulin delivery, a new wave of biotech innovation is reshaping the future of diabetes treatment and investment
Research & Development

Med Uni Graz researchers present a new approach to targeted therapy for leukaemia

Acute myeloid leukaemia (AML) is a cancer of the haematopoietic cells that causes the uncontrolled proliferation of certain immature blood cells
Manufacturing

When science meets security: the future of small molecule outsourcing

Looking across 2025 and into 2026, chemical and pharmaceutical manufacturing is navigating a period of rapid transition, with trends emerging that will influence competitiveness for years to come
Research & Development

Research shows that Pepaxti is effective in high-risk myeloma

Oncopeptides announces new research demonstrating that Pepaxti (melflufen) maintains its anti-myeloma activity in patients with high-risk genetic features, including deletion 17p (del(17p)) and TP53 mutations
Research & Development

Biologics at a turning point: complexity, AI and the road to 2026

Despite rapid change, the growing complexity of biologics and the rise of AI-driven design are reinforcing the increasing need for deep scientific expertise and innovation leadership, says Campbell Bunce (CB), Chief Scientific Officer at Abzena
Research & Development

CHITOSE and FUJIFILM Biosciences form strategic alliance to drive global innovation and biopharmaceutical manufacturing

Collaboration formed to accelerate biopharmaceutical manufacturing, combining high-performing CHO-MK cells and GMP-manufactured culture media
Subscribe now